INTRODUCTION

E
PIGENETIC REGULATION INVOLVES a mechanism of gene expression regulation that does not involve changes in the DNA sequence such as DNA methylation, histone modification, chromatin remodeling, and noncoding RNA. 1 Epigenetics plays an important role in regulation of gene expression associated with cell development and differentiation as well as accurate transcriptional regulation. 2 However, it is well known that disruption of the epigenetic machinery is closely associated with carcinogenesis and cancer progression. 3 In recent years, research on epigenetics has significantly accelerated with the development of next generation sequencing (NGS). In this review article, we describe recent findings in epigenetic research in hepatocellular carcinoma (HCC).
DNA METHYLATION
T HE CPG ISLANDS are regions of DNA sequences or islands often found in promoters at the 5 0 -end of the transcript. They play a role in gene expression. The regulation of gene expression by DNA methylation involves control of tissue-specific gene expression as well as the epigenetic phenomenon of genomic imprinting that controls which different alleles are expressed as well as X chromosome inactivation. 4, 5 DNA methylation plays an important role in the normal development of an individual. In mammals, of the DNA methyltransferase (DNMT) family of enzyme catalysts, DNMT1 is involved in DNA replication, whereas DNMT3A/3B is involved in new DNA methylation patterns. 6 Overexpression of DNMT1 and DNMT3A has been observed in many cancers. 7 In cancers, genome-wide low DNA methylation and hyper-DNA methylation areas are present. 8 A low degree of genome-wide methylation is the basis of chromosomal instability while the methylation-mediated inactivation of tumor suppressor gene promoters is an important mechanism in the development of cancer.
Silencing of tumor suppressor genes by DNA hypermethylation
DNA methylation in promoters is well known for silencing genes in HCC. As a result, a high frequency of suppression of p16, E-cadherin, Ras association domain family member 1A (RASSF1A), Runt related transcription factor 3 (RUNX3), suppressor of cytokine signaling 1 (SOCS1), and other tumor suppressor genes has been observed. [10] [11] [12] [13] [14] In a recent comprehensive analysis, it was shown that a high rate of multiple simultaneous methylation in colon cancer, brain tumors, and some cases of breast cancer presented with the CpG island methylator phenotype (CIMP). [15] [16] [17] Furthermore, it is known that, in CIMP phenotype positive tumors, methylation of the DNA mismatch repair gene MutL homolog 1 (MLH1) occurs, resulting in microsatellite instability. 18 CpG island methylator phenotype analysis is also being undertaken for HCC. Hepatocellular carcinoma with CIMP is characterized by upregulated telomerase activity, increased AFP levels, and worse prognosis. [18] [19] [20] The CIMP status of genes, such as adenomatosis polyposis coli (APC), Wnt inhibitory factor 1 (WIF-1), RUNX3, DLC-1 Rho GTPase activating protein (DLC-1), stress-associated endoplasmic reticulum protein 1 (SFRP-1), Dickkopf WNT signaling pathway inhibitor (DKK), and E-cadherin, associate with higher metastatic rate and recurrence rate and could be assessed using plasma sample as a prognostic marker. 21 A recent study implicated epigenetic interaction between DNA methylation and histone modifications. H3K4 methylation can protect gene promoters from de novo DNA methylation in cancer cells. 22 Therefore, de novo methylation is closely associated with the removal of methylation from H3K4 by lysine demethylase 1A (KDM1A) and AT-rich interaction domain 1A/1B (ARID1A/1B) on the certain gene loci. Subsequently, DNMT3A/DNMT3B-DNMT3L complexes can induce de novo methylation after the removal of H3K4 methylation. 23 Collectively, DNA methylation plays a central role in cancer development. KDM1A is upregulated in HCC tissues and more KDM1A-positive cells are observed in the higher tumor stage. 24 It is also reported that high ARID1A expression is associated with poor survival in patients with HCC. 25 
Ten-eleven translocation (TET) enzymes
The TET family of enzymes, including TET1, TET2, and TET3, catalyze the hydroxylation of the methylated base of 5-methylcytosine (5mC) to generate 5-hydroxymethcytosine (5hmC) in an α-KG dependent reaction. 26 5-Methylcytosine can be removed by thymine DNA glycosylase and, through this repair, the demethylation process is considered to be promoted. 27 The TET2 gene has been identified as mutating at a high frequency in myeloid malignancies, including acute myeloid leukemia (AML). 28 Lowered TET2 enzymatic activity, due to a mutation of the TET2 gene, interferes with conversion of 5mC to 5hmC. This results in increased DNA methylation levels. However, somatic mutations affecting TET genes are not common in a variety of solid tumors, including HCC. 29 However, decreased expression of TET proteins and lower 5hmC levels are generally observed in these tumors and these alterations are associated to unfavorable clinical outcome in HCC patients. 30 Of interest, it has also been reported that hepatitis B virus (HBV) infection was associated with global genomic 5hmC decrease in HCC. 31 In solid tumors, tumor hypoxia induces a loss of TET activity, which results in an increase in hypermethylation at tumor-suppressor gene promoters in vitro in a variety of cancers, including HCC. 32 Considering that hypoxia protected HCC cells against sorafenib by the induction of hypoxia-inducible factor 1 expression, 33 sorafenib resistance could be in part attributed to DNA hypermethylation followed by TET inactivation.
HISTONE MODIFICATION
H ISTONES, THE CHIEF protein component of chromatin, can undergo post-translational chemical modifications of the histone N-terminal tail, such as acetylation, methylation, phosphorylation, and ubiquitylation. 34, 35 Histone-modifying enzymes dynamically regulate the increase or decrease of histone modifications. 36 For example, the opposing enzymatic activities of histone acetyltransferases and histone deacetylases (HDAC) determine the acetylation status of histone tails. 37 Acetylation of histone H3 at lysine 9 (H3K9ac) and H3K27 (H3K27ac) lead to higher activation of transcription as acetylated histones are often found in gene enhancer and promoter regions. Transcription regulation by histone methylation involves a balance, or interplay, between histone methyltransferase and histone demethylase. The trimethylation of H3K4 and H3K36 (H3K4me3 and H3K36me3) is generally associated with transcriptional activation, whereas the trimethylation of histone H3K9, H3K27, and H3K20 (H3K9me3, H3K27me3, and H3K20me3) represents a hallmark of transcriptional repression at target gene loci. 38 The trithorax group of proteins activate gene transcription by inducing trimethylation of histone H3 at lysine 4 (H3K4me3) at specific sites in chromatin, whereas the Polycomb complexes repress transcription by generating the methylated form of lysine 27 on histone 3 trimethylation (H3K27me3). Both form complexes that are responsible for histone modification. 39 Polycomb complexes can be functionally separated into at least the following two distinct complexes: an initiation complex, Polycomb repressive complex (PRC) 2, and a maintenance complex, PRC1 (Fig. 1) . Recently, BCL6 corepressor (BCOR) and BCOR like 1 (BCORL1) were identified as members of non-canonical PRC1. 40 Fusion transcripts of wild-type BCORL1 and E74 like ETS transcription factor 4 (ELF4) genes are detected in not only myeloid malignancies but also HCC tissues. 41 Although BCORL1 seems to function as a transcriptional corepressor, its functional role remains unclear. Further analysis would be necessary.
H3K27-specific methyltransferases
Enhancer of zeste 2 PRC2 subunit (EZH2), which is a core molecule of PRC2, possesses catalytic activity specific for the trimethylation of H3K27. 42 In B-cell lymphoma, somatic mutations at EZH2 Y641 lead to increased levels of H3K27me3, whereas in bone marrow tumors such as myelodysplastic syndrome and AML, H3K27me3 levels are lowered. 43 It is unusual that a mutation in one gene in a disease results in a gain-of-function or a lossof-function. Although an increase in EZH2 expression has been reported for some solid tumors, such as melanoma, there are few reports of mutations. 44 We have previously reported that EZH2 knockdown and EZH2 inhibitor treatment impaired cell growth and xenograft tumor formation in HCC. 45 Provided that a high level of EZH2 expression in tumors was observed in >50% of HCC patients, EZH2 can be considered as a potent therapeutic target for HCC. 46 Recently, there have been an increasing number of reports that EZH2 phosphorylation has an influence on histone modification. AKT-mediated phosphorylation of EZH2-Ser21 suppresses binding to histone H3, resulting in reduced levels of H3K27me3. 47 Phosphorylation of EZH2 at Thr311 by AMP-activated protein kinase disrupts the interaction between EZH2 and Polycomb repressive complex 2 subunit (SUZ12) and reduces methylation of H3K27, leading to suppression of tumor growth. 48 Although cyclin-dependent kinase 1(CDK1)-dependent phosphorylation of EZH2 at Thr487 leads to reduction of levels of H3K27me3, it induces resistance to tyrosine kinase inhibitors. 49 Furthermore, it has been recently reported that methylation of non-histone proteins by EZH2 can affect the viability and growth of cancer cells in a variety of cancers (Table 1) . [50] [51] [52] [53] 
H3K9-specific methyltransferases
Although H3K27 methylation is primarily achieved by EZH2 within PRC2, H3K9 methylation is implemented by different H3K9-specific lysine N-methyltransferases (KMTs). H3K9me3 in the vicinity of the centromeres is associated with transcriptional repression and regulated by histone lysine methyltransferases such as suppressor of variegation 3-9 homolog 1 (SUV39H1). 54 In Suv39h1-mutant mice, loss of the Suv39h1 histone methyltransferases impairs chromosome stability, leading to B-cell lymphoma. 55 Similarly, SET domain bifurcated 1 (SETDB1) enzymatically and specifically methylates H3K9, contributing to euchromatin gene silencing. In a zebrafish model, SETDB1 accelerated melanoma development. 56 In HCC surgical samples, the expression of SUV39H1 and SETDB1 were higher in tumor tissues than in corresponding non-tumor tissues. 57 High levels of SUV39H1 expression have been shown to correlate with cancer recurrence. Loss-of-function of SUV39H1, but not SETDB1, inhibits cell growth ability and tumorigenicity in HCC cells.
G9a is also H3K9-specific KMT, and it causes the transcriptional repression of target genes through the demethylation of H3K9 (H3K9me2). In a pathological study using resected HCC samples, more than half of the samples showed accelerated expression of this enzyme and a positive correlation in expression levels of G9a and H3K9me2 was observed in these samples. 58 Furthermore, knockdown of G9a using hepatoma cells greatly reduced H3K9me2 levels, leading to reduction of cell growth and tumorigenicity. Comprehensive analyses using NGS successfully identified 96 candidate direct targets for G9a, including tumor suppressor p21WAF1/CIP1. Considering that p21WAF1/CIP1 is suppressed by HDAC inhibitors in HCC cells, 59 this suggests that not only histone acetylation but also methylation is involved in the suppression of p21WAF1/CIP1 expression.
CHROMATIN REMODELING
C HROMATIN REMODELING IS a molecular mechanism that facilitates modification of the chromatin architecture to enable regulation at the gene expression level. 60 There are four families of ATP-dependent chromatin-remodeling factors (SWI/SNF, ISWI, CHD, and INO80). 61 Amon them, the SWI/SNF family is a nucleosome remodeling complex, consisting of a large complex of subunits, that is involved in ATP-dependent removal of nucleosomes or suppression of transcription. The human SWI/SNF family has two distinct complexes, BRG1/hBRM-associated factors (BAF) and polybromoassociated BAF (PBAF). 62 Recent whole-genome sequencing analysis revealed that multiple chromatin regulators, including ARID1A, ARID1B, ARID2, MLL, and MLL3, were frequently mutated. 63 In this study, somatic mutations or indels were detected in at least one of these chromatin regulators in approximately 50% of HCC patients.
AT-rich interaction domain 1A/1B
AT-rich interaction domain 1A is an important component of the BAF chromatin remodeling complex. Its mutations are seen in approximately 30% of HCCs. 64, 65 The decreased expression of ARID1A is reportedly associated with poor prognosis and promotes metastases of HCC. 66 Interestingly, a recent report showed that ARID1A promotes cancer initiation by increasing oxidative stress, diminishing ARID1A expression, and accelerating cancer progression and metastasis. 67 Loss-of-function of ARID1A results in angiogenesis of HCC through upregulation of Ang2 caused by H3K27ac of the Ang2 gene locus. 68 In addition, although ARID1B can partially preserve SWI/SNF functionality when ARID1A is deficient, abnormalities in SWI/SWF targeting and control of enhancer activity cause extensive dysregulation of gene expression. 69 Collectively, ARID1A appears to function as a tumor suppressor. Findings of a recent study revealed that EZH2 inhibition in ARID1A-mutated ovarian cancer upregulates PI3K interacting protein 1, which is a negative regulator of PI3K that causes cell growth inhibition and apoptosis induction in a synthetically lethal manner. 70 This finding implicates the possibility that EZH2 might act as a novel treatment strategy for cancers involving ARID1A mutations.
AT-rich interaction domain 2
A high frequency of mutations in HCC has been observed in ARID2 as well as ARID1A, which are part of the PBAF complex core. 71 Oba et al. reported that ARID2-deficient HCC is vulnerable to UV light-caused DNA damage as a result of disruption of the DNA repair process. 72 In addition, 
NON-CODING RNA
T HE RESULTS OF large-scale RNA-sequencing analysis have shown the existence of large sequence areas in the human genome that could not be accounted for by the primary acid sequence of a protein, or non-coding RNA (ncRNA). 73 Non-coding RNA are divided into two RNA types: small ncRNAs (sncRNAs; <200 nucleotides) and long ncRNAs (lncRNAs; >200 nucleotides). 74 MicroRNA (miRNA) is a representative of the sncRNA that induces gene silencing by binding to complementary target sites within the 3 0 -untranslated region (UTR) of the targeted mRNA by suppressing protein synthesis and/or initiating mRNA degradation. 75, 76 Long ncRNAs can bind to RNA binding protein and suppress protein-protein activities, localization, and protein-protein interactions. 77 Furthermore, excised introns during transcription can fuse to form a covalently closed loop, resulting in circular RNAs (circRNA) that are intracellularly retained, and circRNA has been reported to play a role in the carcinogenesis of cancer. 78 Abnormal expression patterns of ncRNA are implicated in cancer and other diseases (Fig. 2) .
MicroRNA
MicroRNAs are small RNA molecules containing 20-22 nucleotides. MicroRNAs bind to the 3 0 -UTR of the target mRNAs by the seed sequence, which are situated at positions 2-7 from the miRNA 5 0 -end. MicroRNAs regulate expression of many genes by inhibiting translation or accelerating degradation of mRNAs. 75, 76 Thus, miRNAs regulate gene expression at the post-transcriptional phase and are a key component of epigenetic machinery in many diseases. In HCC, miRNAs are involved in carcinogenesis, progression, and metastasis, and have been reported to be a factor in whether the cancer is susceptible to treatment in many reports. 79, 80 In addition, miRNAs are found in secreted exosomes and other extracellular vesicles, which suggests that they play a potentially important role in exosome-mediated cross-talk in cancer. Due to the fact that miRNA can be found in the blood as naked RNA or within exosomes, there is much interest in miRNAs as biomarkers for use in liquid biopsy. 81 Aberrant miRNA expressions observed in HCC are listed in Table 2 .
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Long ncRNA
Long ncRNAs are involved in epigenetic-mediated regulation. Long ncRNA can regulate transcription by binding chromatin-modifying complexes, RNA polymerase II (Pol II), or other transcriptional regulators. Long ncRNAs also modulate RNA processing or post-transcriptional regulation by modification of mRNA translation, RNA turnover, or miRNA-mediated repression. 77 Long ncRNAs play a role in cell differentiation, carcinogenesis, disease, and other processes in the living body. 110 With the initial observation of increased lncRNA H19 expression in liver cancer, increased expressions of lncRNAs have been reported in many other tumor tissues. 111 However, a recent report shows that the lncRNA H19 is downregulated in HCC tissues compared with surrounding non-tumor tissues by H19 promotor methylation. 112 Treatment using 5-azacytidine, a DNA demethylating agent, re-induces H19 expression and suppresses chemoresistance and tumorigenesis. HOX transcript antisense RNA (HOTAIR) represses gene expressions at the HOXD locus. 113 It affects reprogramming of chromatin by binding to PRC2 and LSD1, which cause trimethylation of H3K27 and demethylation of H3K4, respectively. 114 Overexpression of HOTAIR is strongly associated with an unfavorable prognosis for patients with several solid cancers, including HCC. 115 The inhibition of HOTAIR results in cell growth inhibition and epithelial-mesenchymal transition. 116 Furthermore, it was reported that H19 and HOTAIR are expressed in cancer stem cells, 117 which can play a major role in the chemoresistance of cancers. Hepatocellular carcinoma upregulated lncRNA (HULC) is an lncRNA identified by Panzitt and colleagues in 2007. 118 The elevation of HULC by hepatitis B virus X protein promotes hepatoma cell proliferation by downregulating p18.
119
Recent whole-genome sequencing analyses detected many somatic mutation and copy number variation in lncRNAs observed in HCC. 120, 121 These findings imply that dysregulation of ncRNAs, such as lncRNAs, plays important roles in hepatocarcinogenesis.
Circular RNA
Human circRNA usually contains two to three exons with a length of several hundred to several thousand nucleotides. 122 Since the first discovery of human endogenous circRNA in 1991, with advances in RNA sequencing, more and more circRNAs have been found. 123 The diversity of circRNA is reflected by the identification of several thousand types of known circRNA. Although initially thought to be a byproduct of the RNA processing pathway and found in very low concentrations, recent research findings have revealed the various functions of circRNA. With respect to a role in gene expression regulation, a subset of circRNA can function as miRNA sponges, which remove the inhibitory effect of miRNA and further upregulate the expression of the target gene. 124, 125 Although circRNA is usually found in the cytoplasm of a cell, it has been reported that a small subset of circRNA from introns can regulate transcription by binding to Pol II. 126, 127 In general, the expression level of circRNA is low; however, advances in high-throughput sequencing have revealed that, in cancer including HCC, the circRNA expression level changes, which suggests its role in carcinogenesis (Table 3) . [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] Specific circRNA expression according to cell type and tissue is understood and, because circRNA is more stable than linear RNA, the role of circRNA as a diagnostic as well as a prognostic biomarker is anticipated. 139 
CONCLUSIONS
M
ANY EPIGENETIC ABNORMALITIES have been found in liver at a high frequency and the importance of this observation cannot be doubted. Currently this epigenomic change is being used as a biomarker for diagnosis, in clinical trials of epigenetic drugs, as well as in add-ons to drugs currently used, such as multikinase inhibitors. 140, 141 As the future development of therapy targeting epigenetic abnormalities is an important and urgent issue, it is believed that the importance of epigenetic drug discovery research will only continue to increase.
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